NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B

Аnalogues of nucleos(t)ides (AN) such as lamivudine (LAM), telbivudine (TBV), adefovir (ADP), entecavir (ENT) are widely used for the treatment of chronic hepatitis B (CHB). However, the prolonged treatment using these drugs often leads to the development of drug resistance. The most common substitu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: E. A. Elpaeva, A. B. Komissarov, M. M. Pisareva, M. P. Grudinin, O. I. Kiselev
Formato: article
Lenguaje:RU
Publicado: Sankt-Peterburg : NIIÈM imeni Pastera 2015
Materias:
Acceso en línea:https://doaj.org/article/73e7b12f7c62459c89cc46bc5313ea23
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:73e7b12f7c62459c89cc46bc5313ea23
record_format dspace
spelling oai:doaj.org-article:73e7b12f7c62459c89cc46bc5313ea232021-11-22T07:09:47ZNEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B2220-76192313-739810.15789/2220-7619-2015-3-265-272https://doaj.org/article/73e7b12f7c62459c89cc46bc5313ea232015-12-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/331https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Аnalogues of nucleos(t)ides (AN) such as lamivudine (LAM), telbivudine (TBV), adefovir (ADP), entecavir (ENT) are widely used for the treatment of chronic hepatitis B (CHB). However, the prolonged treatment using these drugs often leads to the development of drug resistance. The most common substitutions in the reverse transcriptase are methionine for valine (rtM204V), or methionine for isoleucine (rtM204I) at position 204. Early AN-resistant mutations detection is of great importance to determine the treatment strategy of patients with CHB. Currently there are many highly sensitive methods for detection of drug resistance mutations, such as next-generation sequencing, reverse hybridizationbased line probe assay (LiPA), mass spectrometry. However, these methods require expensive equipment and reagents, and they are not widely used in clinical laboratories. The aim of this study was to develop a simple and accurate real-time PCR method for detection of rtM204I/V mutation. This method showed high specificity and sensitivity (1000 copies/ml), it is less laborious and does not require additional equipment, fast and cost effective compared to other methods. HBV mutations of resistance to AN were determined in 5 groups of patients with CHB. Patients of the first group received monotherapy with pegylated interferon (n = 12), the second group — lamivudine (n = 10), the third group — telbivudine (n = 7), the fourth group — entecavir (n = 15). The fifth group consisted of patients who did not receive antiviral therapy (n = 3). The frequency of mutations in HBV polymerase YMDD-motif was determined among 47 patients with CHB: it was 10% for lamivudine treated patients, 20% — for entecavir, 28% — for telbivudine. YIDD/YVDD motifs were identified in two patients and YMDD/YIDD — in one patient. Real-time PCR method for the detection of AN-resistant rtM204I/V mutations in HBV polymerase can be used in routine diagnostics for primary screening of patients not responding to AN treatment. The application of this method can reduce the number of samples for in-depth study of primary and compensatory mutations of resistance to AN by sequencing method. The developed method versus Sanger-sequencing is fast, economical, and provides the detection of minor variants of HBV populations.E. A. ElpaevaA. B. KomissarovM. M. PisarevaM. P. GrudininO. I. KiselevSankt-Peterburg : NIIÈM imeni Pasteraarticlehepatitis b virusreal-time pcrmutationssequencingchronic hepatitis bаnalogues of nucleos(t)idesInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 5, Iss 3, Pp 265-272 (2015)
institution DOAJ
collection DOAJ
language RU
topic hepatitis b virus
real-time pcr
mutations
sequencing
chronic hepatitis b
аnalogues of nucleos(t)ides
Infectious and parasitic diseases
RC109-216
spellingShingle hepatitis b virus
real-time pcr
mutations
sequencing
chronic hepatitis b
аnalogues of nucleos(t)ides
Infectious and parasitic diseases
RC109-216
E. A. Elpaeva
A. B. Komissarov
M. M. Pisareva
M. P. Grudinin
O. I. Kiselev
NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
description Аnalogues of nucleos(t)ides (AN) such as lamivudine (LAM), telbivudine (TBV), adefovir (ADP), entecavir (ENT) are widely used for the treatment of chronic hepatitis B (CHB). However, the prolonged treatment using these drugs often leads to the development of drug resistance. The most common substitutions in the reverse transcriptase are methionine for valine (rtM204V), or methionine for isoleucine (rtM204I) at position 204. Early AN-resistant mutations detection is of great importance to determine the treatment strategy of patients with CHB. Currently there are many highly sensitive methods for detection of drug resistance mutations, such as next-generation sequencing, reverse hybridizationbased line probe assay (LiPA), mass spectrometry. However, these methods require expensive equipment and reagents, and they are not widely used in clinical laboratories. The aim of this study was to develop a simple and accurate real-time PCR method for detection of rtM204I/V mutation. This method showed high specificity and sensitivity (1000 copies/ml), it is less laborious and does not require additional equipment, fast and cost effective compared to other methods. HBV mutations of resistance to AN were determined in 5 groups of patients with CHB. Patients of the first group received monotherapy with pegylated interferon (n = 12), the second group — lamivudine (n = 10), the third group — telbivudine (n = 7), the fourth group — entecavir (n = 15). The fifth group consisted of patients who did not receive antiviral therapy (n = 3). The frequency of mutations in HBV polymerase YMDD-motif was determined among 47 patients with CHB: it was 10% for lamivudine treated patients, 20% — for entecavir, 28% — for telbivudine. YIDD/YVDD motifs were identified in two patients and YMDD/YIDD — in one patient. Real-time PCR method for the detection of AN-resistant rtM204I/V mutations in HBV polymerase can be used in routine diagnostics for primary screening of patients not responding to AN treatment. The application of this method can reduce the number of samples for in-depth study of primary and compensatory mutations of resistance to AN by sequencing method. The developed method versus Sanger-sequencing is fast, economical, and provides the detection of minor variants of HBV populations.
format article
author E. A. Elpaeva
A. B. Komissarov
M. M. Pisareva
M. P. Grudinin
O. I. Kiselev
author_facet E. A. Elpaeva
A. B. Komissarov
M. M. Pisareva
M. P. Grudinin
O. I. Kiselev
author_sort E. A. Elpaeva
title NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
title_short NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
title_full NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
title_fullStr NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
title_full_unstemmed NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
title_sort new method for determining hepatitis b virus resistance mutations m204i/v to nucleos(t)ide analogues in patients with chronic hepatitis b
publisher Sankt-Peterburg : NIIÈM imeni Pastera
publishDate 2015
url https://doaj.org/article/73e7b12f7c62459c89cc46bc5313ea23
work_keys_str_mv AT eaelpaeva newmethodfordetermininghepatitisbvirusresistancemutationsm204ivtonucleostideanaloguesinpatientswithchronichepatitisb
AT abkomissarov newmethodfordetermininghepatitisbvirusresistancemutationsm204ivtonucleostideanaloguesinpatientswithchronichepatitisb
AT mmpisareva newmethodfordetermininghepatitisbvirusresistancemutationsm204ivtonucleostideanaloguesinpatientswithchronichepatitisb
AT mpgrudinin newmethodfordetermininghepatitisbvirusresistancemutationsm204ivtonucleostideanaloguesinpatientswithchronichepatitisb
AT oikiselev newmethodfordetermininghepatitisbvirusresistancemutationsm204ivtonucleostideanaloguesinpatientswithchronichepatitisb
_version_ 1718418047741460480